Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands, except share and per share amounts) | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $8,968 | $23,194 | $13,178 | $108,123 |
| Operating expenses: | ||||
| Research and development | 47,964 | 30,653 | 92,033 | 62,843 |
| General and administrative | 10,134 | 8,095 | 20,309 | 16,798 |
| Total operating expenses | 58,098 | 38,748 | 112,342 | 79,641 |
| (Loss) income from operations | (49,130) | (15,554) | (99,164) | 28,482 |
| Other income: | ||||
| Interest income | 5,916 | 3,068 | 11,507 | 6,507 |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s G&A?
- Monte Rosa Therapeutics, Inc. (GLUE) reported G&A of $10.13M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s G&A changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s G&A increased by 25.2% year-over-year, from $8.1M to $10.13M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s G&A has grown at a 23.3% compound annual growth rate (CAGR), from $15.73M to $36.38M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Monte Rosa Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude